학술논문
Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study
Document Type
Article
Author
Source
In: Annals of oncology : official journal of the European Society for Medical Oncology . (Annals of oncology : official journal of the European Society for Medical Oncology, 1 October 2018, 29:viii359)
Subject
Language
English
ISSN
15698041